Programmatic Advertising for Medical Device Marketing
How programmatic medical device marketing differs from pharma: FDA and FTC device rules, surgeon and facility audiences, DTC devices, and measurement.
The short answer
Programmatic advertising for medical device marketing uses the same DSPs and data as pharma, but the audiences and rules differ. The buyer is often a surgeon, a value analysis committee, or a hospital, not a prescriber writing scripts. FDA regulates restricted device ads while the FTC covers many others, and claims must stay within the cleared or approved indication. Measure accounts and procedures, not clicks.
Device marketers often inherit pharma media playbooks because agencies and data partners serve both. Some of it transfers. Much of it does not. A drug is chosen by a prescriber and filled at a pharmacy. A surgical device may be chosen by a surgeon, approved by a hospital committee, purchased through a group purchasing organization, and paid for under a bundled procedure rate. Media has to reach more than one of those people, and the outcome is harder to see. The broader comparison across healthcare advertiser types sits in the guide to programmatic advertising in healthcare.
How medical device marketing differs from pharma
| Factor | Pharma (Rx) | Medical devices |
|---|---|---|
| Primary regulator for ads | FDA (OPDP) | FDA for restricted devices; FTC for many non-restricted devices |
| Main decision maker | Prescriber, with payer influence | Surgeon or specialist, plus facility buyers and committees |
| Audience size | Hundreds to hundreds of thousands of HCPs | Often a few hundred to a few thousand proceduralists |
| Outcome data | Prescription claims, widely used for measurement | Procedure claims, sales and CRM data, account purchases |
| Sales cycle | Per prescription | Months for capital equipment, faster for consumables |
| DTC role | Large for many brands | Large for some (hearing, diabetes devices, aesthetics, orthopedics), absent for others |
FDA device rules that shape the media plan
This is a summary for planning, not regulatory advice. Device advertising rules depend on the device classification and whether it is a restricted device. For restricted devices, FDA requires ads to include a brief statement of intended uses and relevant warnings, precautions, side effects, and contraindications. Labeling for devices falls under 21 CFR Part 801. For many non-restricted devices, advertising falls under FTC authority, which requires claims to be truthful and substantiated.
The rule that matters most for media teams is simple: claims have to stay within the cleared or approved indication. A device cleared through 510(k) for one use cannot be marketed for a different one. That affects contextual targeting too. A contextual segment that places a device ad next to content about an off-label use can raise questions even if the ad itself is on label, so reviewers often want to see the context list, not just the creative.
Device companies also have Sunshine Act obligations. Payments and transfers of value to physicians and teaching hospitals are reported through CMS Open Payments, which matters if media programs include sponsored education or meals at events.
Targeting surgeons, specialists, and facilities
Surgeons and proceduralists
The base is an NPI list filtered by specialty and, where data allows, procedure volume. Interventional cardiologists, spine surgeons, and orthopedic surgeons are small groups, so match rates and frequency caps matter a lot. Endemic placements (surgical journals, society sites, specialty news) carry much of the load. Conference timing is a useful dynamic layer, since attention to device news peaks around major meetings.
Facilities and buying committees
Capital equipment decisions involve hospital administrators, supply chain leaders, and value analysis committees. These are B2B audiences, reached through account-based targeting on business identity graphs and business publishers. Whether to target the individual, the practice, or the system is covered in choosing the targeting unit, and the B2B parallels are in HCP marketing as B2B marketing.
Patients, for DTC devices
For devices that patients ask for (CGMs, hearing aids, certain orthopedic and aesthetic procedures), DTC programmatic looks closer to pharma DTC: contextual, condition audiences with provenance checks, CTV and online video, and search support. The privacy questions are the same, and consumer health data laws apply. The options are compared in the healthcare programmatic targeting options article.
Measurement for device campaigns
Device measurement is less standardized than pharma Rx lift. Common approaches:
- Account-level comparison. Split target accounts (hospitals, ASCs, practices) into exposed and holdout groups, then compare evaluations, purchases, or procedure growth.
- Procedure claims. Where available, match exposed surgeons to procedure volume, using a comparison group.
- CRM and sales data. Tie media exposure to demo requests, rep meetings, and opportunity stages, with the caution that reps also target the same accounts.
- Geo tests for DTC. Compare consultation requests or procedures in targeted versus matched markets.
A hypothetical example: a device company targets 300 accounts and holds out 100 matched accounts. Over two quarters, 45 exposed accounts (15 percent) start a product evaluation, compared with 10 holdout accounts (10 percent). The estimated lift is 5 percentage points, or about 15 additional evaluations across the 300 exposed accounts. Whether that pays back depends on evaluation-to-purchase rates and deal size, which sales operations should supply.
What usually goes wrong in device programmatic
- Running pharma-style frequency against a surgeon list of 800 people, which burns out the audience in weeks.
- Ignoring the facility buyers entirely and wondering why surgeon interest does not turn into purchases.
- Reporting impressions and CTR to a sales organization that measures quota, which makes media look irrelevant.
- Letting contextual or audience segments wander into off-label topics.
Practical takeaway
Write down every role involved in the purchase decision for your device (surgeon, administrator, committee, patient) and assign each one a targeting method and a measurable outcome. Then set up an account-level holdout before launch, so the first sales review compares exposed and unexposed accounts instead of debating clicks.
Frequently asked questions
Who regulates medical device advertising?
FDA regulates advertising for restricted devices, and the FTC generally regulates advertising for non-restricted devices, under its truth-in-advertising authority. Labeling for all devices falls under FDA rules. Which applies depends on the device, so confirm with regulatory before planning claims.
How do you target surgeons with programmatic advertising?
Start from NPI lists filtered by specialty and procedure volume, then add endemic surgical publishers, society sites, and conference periods. Because surgeon audiences are small, precision and match quality matter more than scale.
How is medical device advertising measured?
For surgeon and facility campaigns, measure engagement and sales outcomes at the account level, such as demo requests, evaluations, and procedure growth in exposed accounts against unexposed ones. For DTC devices, measure leads, consultations, and procedures with a geographic or audience holdout.
Sources
- FDA, Overview of Device Regulation
- eCFR, 21 CFR Part 801, Labeling
- FTC, Health Products Compliance Guidance
- CMS, Open Payments
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.